Mike Ryskin is a Director in Equity Research on the Life Science Tools & Diagnostics team, as well as being lead analyst on the Animal Health sector, and has been with Bank of America since 2015. Previously, he was an Oncology Research Scientist at Pfizer, working on a number of Discovery/Pre-clinical projects in epigenetics. He has an MBA from New York University, an MA in Molecular Biology from Brown University, and an BA in Molecular Biology from Cornell University. He is based in New York.
Director, Global Research, BofA Securities